MIGUEL JOSÉ
MARTÍN JIMÉNEZ
Catedrático de universidad
![Foto de MIGUEL JOSÉ](/img/nophoto.png)
![Foto de Institute Paoli-Calmettes](/img/noimage_org.png)
Institute Paoli-Calmettes
Marsella, FranciaPublicacions en col·laboració amb investigadors/es de Institute Paoli-Calmettes (4)
2020
-
Outcomes in clinically relevant patient subgroups from the EMBRACA study: Talazoparib vs physician's choice standard-of-care chemotherapy
JNCI Cancer Spectrum, Vol. 4, Núm. 1
-
Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial
Annals of Oncology, Vol. 31, Núm. 11, pp. 1526-1535
2018
-
Quality of life with talazoparib versus physician's choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: Patient-reported outcomes from the EMBRACA phase III trial
Annals of Oncology, Vol. 29, Núm. 9, pp. 1939-1947
-
Talazoparib in patients with advanced breast cancer and a germline BRCA mutation
New England Journal of Medicine, Vol. 379, Núm. 8, pp. 753-763